Candel Therapeutics, Inc.
NASDAQ: CADL0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Paul-Peter Tak
- Employees
- 38
- Headquarters
- Needham, United States
- IPO year
- 2021
- Market cap
- $508.9M
- Website
- https://www.candeltx.com
Loading CADL…
Loading profile data…Frequently asked questions about CADL
What does Candel Therapeutics, Inc. (CADL) do?
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This the...
Where does CADL trade?
Candel Therapeutics, Inc. (CADL) trades on the NASDAQ Global Market.
What sector is CADL in?
Candel Therapeutics, Inc. (CADL) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Candel Therapeutics, Inc.?
Paul-Peter Tak is the chief executive officer of Candel Therapeutics, Inc. (CADL).
Where is Candel Therapeutics, Inc. headquartered?
Candel Therapeutics, Inc. is headquartered in United States.
Does CADL pay a dividend?
Candel Therapeutics, Inc. (CADL) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CADL go public?
Candel Therapeutics, Inc. (CADL) completed its initial public offering in 2021.